Tour de Cure Grants Committee
Paul Mirabelle - Chairman - Grants Committee
Paul has been involved with Tour de Cure for four years now. He has over 30 years of experience as a business executive and company director. Over this time he has held an extensive range of CEO and director roles within market leading medical service enterprises in both public and private companies. Paul has worked with organisations providing home doctor services, skin cancer diagnostics, digital health information, medical device distribution, audiology/hearing services, radiology services and veterinary medicine. Prior to that he was a partner with The Boston Consulting Group in Sydney and a barrister and solicitor in Canada. He holds an LLB and an MBA with Distinction from the University of Western Ontario in Canada.
Julie Briscoe – TdC Board Sponsor
Julie is a practising lawyer with Polczynski Robinson and specialises as a commercial advisor. She acts as an honorary solicitor at Tour de Cure, having been appointed to the Board in 2010. In addition to her role on the TdC Grants Committee she is also closely involved with Tour de Cure’s Annual Snow Ball event.
Dr Michael McAuliffe
Michael completed his orthopaedic training in Queensland in 2004. He was the Director of Orthopaedics at the Ipswich General Hospital for 4 years from 2006 – 2010. Dr McAuliffe’s main area of expertise is Total Knee Replacements and does around 130 Total Knee Replacements a year. He is a member of the Australian Orthopaedic Association, The Australian Knee Society, The American Hip and Knee Association and a senior lecturer at the University of Queensland. He continues to take part in research and regularly presents at peer reviewed conferences and has multiple peer reviewed publications.
Dr Chuck Bailey
Chuck Bailey is a molecular and cellular biologist with 19 years experience in studying molecular mechanisms of disease and cancer. He is a Senior Research Fellow at the School of Medicine at the University of Sydney and at the Centenary Institute of Cancer Medicine and Cell Biology. Chuck leads a group in the Centenary Institute studying transcription factor biology in cancer. Chuck serves on a number of institutional committees and has a stellar research record having published over 40 articles and reviews that have been cited over 2,100 times with 15 cited more than 50 times.
Professor Andrew McLachlan AM
Andrew is a pharmacist, academic and active researcher with experience in clinical pharmacology and the quality use of medicines. He is Head of School and Dean at the Sydney Pharmacy School, The University of Sydney and former Professor of Pharmacy (Aged Care) at Concord Hospital where he worked with clinicians, researchers and leaders in the health system. Andrew is the former chair of a human research ethics committee and currently serves on a range of Australian committees related to medicines policy, medicines evaluation, regulation, research evaluation and antidoping.
Daren is an experienced Program and Project Manager in large scale IT transformation programs and technology systems integration initiatives based in Brisbane.
Daren has his own personal journey with two unrelated forms of cancer going back to 2013. He has witnessed the devastating impacts this disease has had on his family and friends. As a consumer advocate with strong critical thinking skills, Daren provides a rich perspective in selecting the best projects possible.
Dr Shane Belford
Shane is veterinarian based in Queensland with a background in blood plasma products for use in veterinary medicine. He got the chance to help out during the Ebola crisis in 2014 which was the catalyst for his journey into vital Ebola research. Shane played a key role in the development of an effective and economical treatment for Ebola as part of an international team led by Queensland researchers.
Tracy has a background in institutional investing in South East Asia and institutional asset management consulting in Australia working with some of Australia’s largest companies.
Over the last six years Tracy has been on her own cancer journey. As a consumer advocate Tracy voices the perspectives of patients as well as their families and carers in the selection of projects.
Dr Jennifer A. Byrne
Jennifer Byrne has spent her scientific career analyzing childhood and adult cancers at a molecular level. Her PhD studies mapped loss of chromosome 11p15 loci in embryonal tumours, and she then identified a novel gene family during postdoctoral studies in France. Professor Byrne is Director of Biobanking with NSW Health Pathology, and Professor of Molecular Oncology in the School of Medical Sciences in the Faculty of Medicine and Health.
Jennifer Byrne was previously (Acting) Head of the Children's Cancer Research Unit at The Children's Hospital at Westmead from 2008-2019, and Deputy Director of the Kids Cancer Alliance from 2018-2019.She chaired the Biobanking Sub-committee of Australia and New Zealand Children’s Oncology Group from 2016-2020.
Dr Luke Baker
Dr Luke Baker (MBBS, FRANZCR, FACP, EBIR) graduated from the University of Sydney and completed his specialist training at Westmead Public Hospital and the University Hospital of Alabama in Birmingham. He is subspecialty trained in Body Imaging and Interventional Radiology.
Luke is a fellow of the Royal Australian and New Zealand College of Radiologists and The Australian College of Phlebologists. Qualified as an interventional radiologist, Dr Baker has a special interest in the diagnosis and treatment of cancer, acute hospital-based medicine and venous diseases. He is currently a senior staff specialist and section head of interventional radiology at Westmead Public Hospital.